Abivax shares fall after rival drug data, trader says
Mon 12:47
BUZZ-Abivax shares fall after rival drug data, trader says ** Shares in Abivax ABVX.PA are down around 3%, paring gains after falling as much as 9.9%
** A trader points to rival Gilead's GILD.O pill succeeding in mid-stage bowel disease trial
** Gilead said its experimental once-daily pill emvistegrast reduced symptoms of moderate to severe ulcerative colitis, a chronic bowel illness, in more patients than placebo
** Abivax's obefazimod met the main goal in a late-stage trial in June, and the company said in July it remained on track to submit a New Drug Application to the US Food and Drug Administration by year-end
** Including the session's fall, the stock has dropped by 37% YTD
(Reporting by Lucie Barbier in Gdansk)
Recent news on Gilead Sciences
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
Abivax shares fall after rival drug data, trader says
Brief: Gilead - Emvistegrast 200 Mg Met The Primary Endpoint In Phase 2 Swift Dose-Ranging Study
Gilead's pill succeeds in mid-stage bowel disease trial
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal